Patents Assigned to Eagle Pharmaceuticals, Inc.
-
Patent number: 11872214Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: January 16, 2024Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11844783Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: December 19, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11793813Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.Type: GrantFiled: June 8, 2022Date of Patent: October 24, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Feng-Jing Chen, Steven L Krill
-
Patent number: 11590077Abstract: The present disclosure provides methods of treating breast cancer including administering aqueous suspensions comprising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(10) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.Type: GrantFiled: November 8, 2018Date of Patent: February 28, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Feng-Jing Chen, Steven L. Krill, Rama Abu Shmeis, Adrian Hepner, Charles Wescott, Tara Jaskowski, Michael Joyce
-
Publication number: 20230000874Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.Type: ApplicationFiled: August 30, 2022Publication date: January 5, 2023Applicant: EAGLE PHARMACEUTICALS, INC.Inventors: Feng-Jing CHEN, Steven L. KRILL
-
Publication number: 20220409623Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.Type: ApplicationFiled: August 30, 2022Publication date: December 29, 2022Applicant: EAGLE PHARMACEUTICALS, INC.Inventors: Feng-Jing CHEN, Steven L. KRILL
-
Publication number: 20220409624Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.Type: ApplicationFiled: August 30, 2022Publication date: December 29, 2022Applicant: EAGLE PHARMACEUTICALS, INC.Inventors: Feng-Jing CHEN, Steven L. KRILL
-
Patent number: 11179468Abstract: Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: April 8, 2013Date of Patent: November 23, 2021Assignee: Eagle Pharmaceuticals, Inc.Inventors: Bulusu Bhanu Teja, Nagesh R. Palepu
-
Patent number: 11103483Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: July 12, 2019Date of Patent: August 31, 2021Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20210260076Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.Type: ApplicationFiled: September 16, 2020Publication date: August 26, 2021Applicant: Eagle Pharmaceuticals, Inc.Inventor: Nageswara R. Palepu
-
Publication number: 20210106686Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: May 8, 2020Publication date: April 15, 2021Applicant: Eagle Pharmaceuticals, Inc.Inventor: Srikanth Sundaram
-
Publication number: 20200368355Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: November 26, 2019Publication date: November 26, 2020Applicant: Eagle Pharmaceuticals, Inc.Inventor: Srikanth Sundaram
-
Publication number: 20200282057Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: September 30, 2019Publication date: September 10, 2020Applicant: Eagle Pharmaceuticals, Inc.Inventor: Srikanth Sundaram
-
Patent number: 10363259Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.Type: GrantFiled: October 20, 2017Date of Patent: July 30, 2019Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Nageswara R. Palepu
-
Patent number: 10052385Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: February 14, 2017Date of Patent: August 21, 2018Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 10010533Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: February 14, 2017Date of Patent: July 3, 2018Assignee: EAGLE PHARMACEUTICALS, INC.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9655898Abstract: Long term storage stable pemetrexed-containing liquid pharmaceutical compositions are disclosed. The compositions can include pemetrexed or pharmaceutically acceptable salts thereof; an antioxidant selected from lipoic acid, dihydrolipoic acid, methionine and mixtures thereof; a chelating agent selected from lactobionic acid, sodium citrate, tribasic and mixtures thereof; and a pharmaceutically acceptable fluid. The pH of the compositions is in a range of about 8 to about 9.5. The pemetrexed-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 227 nm, after at least about 18 months of storage at a temperature of from about 5° C. to about 25° C. Methods of preparing the formulation as well as methods of treatment of pemetrexed-susceptible diseases using the same are also disclosed.Type: GrantFiled: July 26, 2011Date of Patent: May 23, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9597398Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: January 28, 2016Date of Patent: March 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 9597397Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: September 17, 2015Date of Patent: March 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 9597399Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: GrantFiled: January 28, 2016Date of Patent: March 21, 2017Assignee: EAGLE PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram